Eiffel to focus on developing inhaled and transdermal insulin
Wednesday, 31 March, 2004
Eiffel Technologies (ASX : EIF) announced today it has completed further animal studies in its development of improved injectable insulin, and would focus resources on collaborations with pharmaceutical companies working on inhaled or transdermal insulin.
The studies confirmed that Eiffels re-engineered insulin is at least equivalent to the commercially available forms of the drug.
Eiffel has supplied re-engineered insulin to companies for use in either oral or transdermal delivery. These companies will be testing Eiffel's product in different delivery devices.
“We must prioritise our insulin research to areas where the technology has the potential to add maximal commercial and shareholder value“, said Eiffel’s Managing Director and CEO, Christine Cussen. “The potential opportunities for inhaled and oral insulin are large and we want to capitalise on these opportunities.”
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
